Rocket Lab Shares Drop 5.5% After Neutron Tank Rupture in Test
Neutron Stage 1 tank testing caused a structural rupture during a controlled hydrostatic trial with no damage to test infrastructure, spurring a 5.5% share drop. Rocket Lab’s record $2B backlog, including an $816M satellite contract, faces potential Neutron debut delays into late 2026 and quarterly cost overruns of $15M.
1. Stage 1 Tank Qualification Rupture Provides Critical Data
During a recent hydrostatic test on Rocket Lab’s Neutron Stage 1 tank, engineers intentionally pushed the composite structure to failure, resulting in a controlled rupture that yielded precise data on pressure tolerances. The incident caused no damage to the test stand or surrounding infrastructure, and Rocket Lab has already commenced production on the next tank iteration. Company engineers will integrate the failure metrics into finite-element models to refine safety margins, accelerate certification protocols and reduce the risk of in-flight structural anomalies.
2. Long-Term Business and Backlog Strength
Rocket Lab’s launch services division reported a firm backlog exceeding $2 billion, including an $816 million satellite constellation contract signed in late 2025. The firm completed its first Electron mission of 2026 and achieved a record 21 Electron launches in the prior year. In parallel, Rocket Lab continues to support NASA’s Artemis program through lunar CubeSat deployments — notably the 2022 CAPSTONE mission that validated near-rectilinear halo orbit operations for the planned Gateway station.
3. Neutron Development Timelines and Financial Risks
Originally targeted for debut in 2024, the Neutron medium-lift rocket has shifted to a first-flight window in mid-2026 due to expanded qualification requirements. Development expenses reached approximately $360 million by December 2025, with additional costs of roughly $15 million per quarter for extended testing. Analysts at BTIG project one test launch plus one commercial flight in 2026, scaling to nine missions by 2029. However, further delays could elevate program spending, intensify cash burn, and necessitate equity raises, placing pressure on valuation multiples predicated on 50%–100% annual revenue growth.